CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Bioventus Q3 revenue rises 3% but misses estimates

By Reuters News


Overview

  • US medtech firm's Q3 revenue rose 3% but missed analyst expectations

  • Adjusted EBITDA for Q3 grew 7% to $28.4 mln, driven by higher revenue and cost management

  • Company continues to review potential strategic alternatives, as previously disclosed


Outlook

  • Bioventus updates 2026 net sales guidance to $590 mln-$595 mln, growth of about 4%-5%

  • Company reaffirms 2026 adjusted EPS guidance of $0.75-$0.79 per diluted share

  • Bioventus sees 2026 adjusted cash from operations at $84 mln-$89 mln


Result Drivers

  • PAIN TREATMENTS GROWTH - Revenue rose 6.2% in Pain Treatments, led by strong volume growth in hyaluronic acid therapy products, PRP system, and PNS products

  • DISCIPLINED COST MANAGEMENT - Adjusted EBITDA advanced due to higher revenue and disciplined cost management, partially offset by increased investments

  • RESTORATIVE THERAPIES DECLINE - Revenue in Restorative Therapies fell 3.4% due to lower volume for the EXOGEN Bone Stimulation System


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Miss

$142.40 mln

$149.46 mln (5 Analysts)

Q3 Adjusted EBITDA

$28.40 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Bioventus Inc. is $18.00, about 35.1% above its October 30 closing price of $13.33

  • The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 15 three months ago


Reuters Recommended Reads

  • Nov 2 - Denmark medical devices maker Coloplast's Q4 revenue rises

  • Nov 2 - IDEXX Laboratories Q3 revenue beats estimates, lifts FY profit outlook

  • Nov 2 - IDEXX raises forecast, betting diagnostics can offset weak vet visits


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.